Skip to main content


Pre Clinical Phase 1 Phase 2 Phase 3


Anthrax Vaccine Candidate
(Anthrax Vaccine Adsorbed with CPG 7909 Adjuvant)
*Phase 3 Study: First subject enrollment targeted for 2019

NuThrax™ (Anthrax Vaccine Adsorbed with CPG 7909 Adjuvant) is being studied for use as a third generation anthrax vaccine. This candidate consists of BioThrax® (Anthrax Vaccine Adsorbed) in combination with a novel immunostimulatory compound, CPG 7909.

Active Clinical Trials

  • No active clinical trials

Completed Clinical Trials



Seasonal Influenza Therapeutic Candidate
Hyperimmune Platform
**Phase 3 Study: First subject enrollment targeted for 2019


Zika Therapeutic Candidate
Hyperimmune Platform
**Phase 1 Study: First subject enrollment targeted for 2018


Burkholderia Therapeutic Candidate
Broad Spectrum Antibiotic

GC-072 is the lead candidate based on Emergent's EV-035 series of broad spectrum antibiotics. These compounds have a novel 4-oxoquinolizine antibacterial backbone showing activity against quinolone-resistant bacterial strains such as Burkholderia pseudomallei.



Pan-filovirus Therapeutic Candidate (Ebola, Marburg, Sudan)
Hyperimmune Platform, Monoclonal Antibody

Clinical Trials Resources

To learn more about Clinical Trials, visit the websites below. These sites are maintained by, a web-based resource that provides patients, their family members, health care professionals, researchers, and the public with easy access to information on publicly and privately supported clinical studies on a wide range of diseases and conditions. is maintained by the National Library of Medicine at the National Institutes of Health.